← back to search

Gianni Tognoni

University of Milano-Bicocca · IT
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Acute Myocardial Infarction Research, and Diabetes, Cardiovascular Risks, and Lipoproteins.
h-index
94
citations
43,403
works
433
NIH funding
primary concept
email

Recent publications

Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets
Neurology 2017cited by 43position: middledoi
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
European Heart Journal 2015cited by 157position: middledoi
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
The Lancet 2014cited by 707position: middledoi
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A model for sustainable development in pediatric oncology
Pediatric Blood & Cancer 2013cited by 94position: middledoi
Interaction Between Baseline and Early Worsening of Renal Function and Efficacy of Renin–Angiotensin–Aldosterone System Blockade in Patients with Heart Failure: Insights from the Val-HeFT Study
European Journal of Heart Failure 2013cited by 63position: middledoi
Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease
Annals of Internal Medicine 2012cited by 205position: middledoi
Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis
American Journal of Kidney Diseases 2012cited by 101position: middledoi
Oxidative Damage, Platelet Activation, and Inflammation to Predict Mobility Disability and Mortality in Older Persons: Results From the Health Aging and Body Composition Study
The Journals of Gerontology Series A 2012cited by 72position: middledoi
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
BMJ Open 2012cited by 47position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Antonio Nicolucci · University of Messina2 papers (2012–2012)Suetonia C. Palmer · University of Otago2 papers (2012–2012)Vlado Perkovic · UNSW Sydney2 papers (2012–2012)Jonathan C. Craig · Murdoch Children's Research Institute2 papers (2012–2012)Angela C Webster · The University of Sydney2 papers (2012–2012)Giusi Graziano · Center for Outcomes Research and Clinical Epidemiology2 papers (2012–2012)Mona Razavian · The George Institute for Global Health2 papers (2012–2012)Fabio Pellegrini · Biogen (United States)2 papers (2012–2012)Giovanni FM Strippoli · The University of Sydney2 papers (2012–2012)Lucia Di Micco · Ospedale Antonio Cardarelli2 papers (2012–2012)Meg Jardine · Smart Material (Germany)2 papers (2012–2012)Robert M. Califf · Tufts University1 papers (2012–2012)Valentino Conter · Amgen (United States)1 papers (2013–2013)Gregory J. Tranah · Sutter Health1 papers (2012–2012)Matteo Cesari · Université Claude Bernard Lyon 11 papers (2012–2012)Albert Kandra · Novartis (Switzerland)1 papers (2013–2013)Guy E.H.M. Rutten · Utrecht University1 papers (2012–2012)Scott C. Howard · University of Tennessee at Knoxville1 papers (2013–2013)Jay N. Cohn · University of Minnesota, Twin Cities1 papers (2013–2013)Raffaele Antonelli Incalzi · Università Campus Bio-Medico1 papers (2012–2012)